Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VE303 for Prevention of Recurrent C. difficile Infection
NCT03788434Phase 2Completed
- Sponsor
- Vedanta Biosciences
- Start
- Feb 2019
- Primary completion
- Jun 2021
- Modality
- Live Biotherapeutic Products
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of VE303 in Clostridioides difficile infection (CDI) (3 arms), sponsored by Vedanta Biosciences. Primary endpoint: Clostridioides Difficile Infection Recurrence at Week 8. Started Feb 2019; status: completed.
02
Drugs
VE303
03
Conditions
Clostridioides difficile infection (CDI)
Beyond the preview
Go deeper on NCT03788434.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03788434.